clonidine has been researched along with Heart Defects, Congenital in 4 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clonidine is a useful analgesic-sedative agent; however, few data exist regarding its use in infants after congenital heart disease surgery." | 1.40 | Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery. ( Arenas-Lopez, S; Durward, A; Manna, S; Mulla, H; Murdoch, IA; Tibby, SM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arenas-Lopez, S | 1 |
| Mulla, H | 1 |
| Manna, S | 1 |
| Durward, A | 1 |
| Murdoch, IA | 1 |
| Tibby, SM | 1 |
| Nguyen, KN | 1 |
| Byrd, HS | 1 |
| Tan, JM | 1 |
| Pohl-Schickinger, A | 1 |
| Lemmer, J | 1 |
| Hübler, M | 1 |
| Alexi-Meskishvili, V | 1 |
| Redlin, M | 1 |
| Berger, F | 1 |
| Stiller, B | 1 |
| Persico, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Dexmedetomidine Versus Morphine as an Adjunct to Bupivacaine in Caudal Anesthesia for Pediatric Thoracic Surgeries. A Randomized Controlled Trial.[NCT04445636] | 50 participants (Actual) | Interventional | 2020-06-28 | Completed | |||
| Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants:[NCT01360450] | Phase 2/Phase 3 | 12 participants (Actual) | Interventional | 2011-07-31 | Terminated (stopped due to The study was treminated because of low accural) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time to complete detoxification is defined as 48 hrs off all opioids/benzodiazepines and study drug with acceptable withdrawal scores of <9 (on average we expect the infant to be enrolled in the study for 2-4 weeks). The scale used to assess withdrawal was the Modified Finnegan Neonatal Withdrawal Scale, which ranges from 0-41, 0 represents no withdrawal and 41 represent maximum withdrawal. (NCT01360450)
Timeframe: up to 4 weeks
| Intervention | days (Mean) | |
|---|---|---|
| total days on narcotics | duration on study drug in days | |
| Control | 37.2 | 14.2 |
| Treatment | 89.5 | 21 |
4 other studies available for clonidine and Heart Defects, Congenital
| Article | Year |
|---|---|
Enteral absorption and haemodynamic response of clonidine in infants post-cardiac surgery.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Clonidine; Drug Administration Schedule; Heart Defects | 2014 |
Caudal analgesia and cardiothoracic surgery: a look at postoperative pain scores in a pediatric population.
Topics: Adolescent; Analgesics; Analgesics, Opioid; Anesthesia, Caudal; Anesthetics, Local; Bupivacaine; Car | 2016 |
Intravenous clonidine infusion in infants after cardiovascular surgery.
Topics: Analgesia; Analgesics; Analgesics, Opioid; Blood Pressure; Body Temperature; Clonidine; Female; Fent | 2008 |
[Pathogenesis and therapy of acute pulmonary edema].
Topics: Acute Disease; Brain Diseases; Cardiac Glycosides; Clonidine; Diuretics; Gas Poisoning; Heart Defect | 1972 |